Dec 04, 2023
|
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
|
Nov 24, 2023
|
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
Nov 16, 2023
|
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
|
Nov 02, 2023
|
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
|
Oct 26, 2023
|
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
|
Sep 05, 2023
|
Chimerix to Participate in Upcoming Investor Conferences
|
Aug 16, 2023
|
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
|
Aug 03, 2023
|
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
|
Jul 27, 2023
|
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
|
Jun 27, 2023
|
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer
|